Beta-blockers in flow of time – view of an anaesthesiologist and intensivist
Authors:
Karel Cvachovec
Authors‘ workplace:
Univerzita Karlova v Praze, 2. lékařská fakulta, Klinika anesteziologie a resuscitace FNM
Published in:
Čas. Lék. čes. 2010; 149: 288-290
Category:
Review Article
Overview
Beta-blockers are used for several decades also for the suppression of symptoms of the adrenergic stress in the perioperative period. While their benefit is considered indisputable there is no consensus on the most suitable patients’ population where benefits would prevail over the risks most significantly. Present trends suggest the shift from the frequent widespread use to the more targeted medication, where the general status of the patient as well as the nature of the operation is being considered. Individual dose should be targeted to the specific therapeutic end-points. While the non-therapeutic use of beta-blockers by lay public is possible there is growing interest in their therapeutic use in severely septic patients. Favourable clinical experience results mostly from their use in the burned patients, where the natural course of the illness has many similarities with the protracted course of severe sepsis. Favourable influence of beta-blockers on monotonous tachycardia with minimal reflex variability of heart rate and on the resulting mortality has been demonstrated. Clinical experience has accumulated up to date reflecting the use of propranolol mostly; the experience with the more cardioselective beta-blockers is mostly experimental. Although there are legitimate worries about possible circulatory depression by beta-blockers empirical data do not support this. There are very encouraging data available about the favourable effect of beta-blockers on the outcome of the traumatised patients, especially patients suffering from a brain trauma.
Key words:
beta- blockers, surgery, burns, sepsis, brain trauma.
Sources
1. London MJ, et al. Perioperative [beta]-Adrenergic Receptor Blockade: Physiologic Foundations and Clinical Controversies. Anesthesiology 2004; 100: 170–175.
2. Stevens RD, Burri H, Tramer M. Pharmacologic Myocardial Protection in Patients Undergoing Noncardiac Surgery: A Quantitative Systematic Review. Anesth Analg 2003; 97: 623–633.
3. Bangalore S, et al. Cardiovascular Protection Using Beta-Blockers. A Critical Review of the Evidence. J Am Coll Cardiol 2007; 50: 159–241.
4. Škarvan K. Perioperační betablokáda. Anest intensiv Med 2007; 18: 286–295.
5. Horáček M. Mají betablokátory stále ještě místo v ochraně myokardu? Anest intensiv Med 2007; 18: 296–300.
6. POISE Study Group: Effects of extended-release metoprolol succinate in patientsundergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839–1847.
7. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade. A Report of the American College of Cardiology Foundation/Američan Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2102–2128.
8. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Risk Management in Non-cardiac Surgery of European Society of Cardiology and endorsed by European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 92–137.
9. Davis E, Loiacono R, Summers RJ. The rush to adrenaline: drugs in sport acting on the beta-adrenergic system. Br J Pharmacol 2008; 154: 584–597.
10. Eliasch H, Rosén A, Scott HM. Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J 1967; 29: 671–683.
11. Taggart P, Carruthers M, Somerville W. Electrocardiogram, plasma catecholamines and lipids, and their modification by oxprenolol when speaking before an audience. Lancet 1973; 302: 341–346.
12. Taggart P, Carruthers M. Supression by oxprenolol of adrenergic respones to stress. Lancet 1972; 300: 256–258.
13. Webster NR, Galley HF. Immunomodulation in the critically ill. Brit J Anaesth 2009; 103: 70–81.
14. Träger K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003; 9: 271–278.
15. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: Propranolol. Crit Care Med 2007; 35(Suppl.): S616–S620.
16. Berk JL, et al. The Treatment of Endotoxin Shock by Beta Adrenergic Blockade. Ann Surg 1969; 169: 74–81.
17. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970; 130: 1025–1034.
18. Berk JL, et al. The treatment of shock with beta adrenergic blockade. Arch Surg 1972; 104: 46–51.
19. Perreira C, et al. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005; 37: 1948–1961.
20. Herndon DN, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J. Med 2001; 345: 1223–1229.
21. Barrow RE, et al. The Use of Beta-Adrenergic Blockade in Preventing Trauma-Induced Hepatomegaly. Ann Surg 2006; 243: 115–120.
22. Werdan K, et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 2009; 87: 266–274.
23. Leibovici L, et al. Relative tachycardia in patients with sepsis: an independent risk factor for mortality. Q J Med 2007; 100: 629–634.
24. Gutierrez J, et al. Effect of beta blockers on sepsis outcome. Med Sci Monit 2009; 15: 499–503.
25. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006; 139: 686–694.
26. Suzuki T, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005; 33: 2294–2301.
27. Schmidt H. et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med 2008; 36: 967–970.
28. Schmittinger CA, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008; 12: R99.
29. Friese RS, et al. Could Beta Blockade Improve Outcome After Injury by Modulating Inflammatory Profiles? J Trauma 2008; 64: 1061–1068.
30. Cotton BA, et al. Beta-Blocker Exposure is Associated With Improved Survival After Severe Traumatic Brain Injury. J Trauma 2007; 62: 26–35.
31. Arbabi S, et al. Beta-Blocker Use is Associated With Improved Outcomes in Adult Trauma Patients. J Trauma 2007; 62: 56–62.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Internal medicine Cardiology General practitioner for adults Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Acoustic neuroma – vestibular schwannoma – personal experience of up-to-date management
- Calcitonin and his role in regulation of calcium-phosphate metabolism
- Beta-blockers in flow of time – view of an anaesthesiologist and intensivist
- Type 2 diabetes mellitus as a subclinical inflammation